These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 32610115)

  • 21. Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
    Simon TG; Roelstraete B; Hagström H; Loomba R; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1366-1373. PubMed ID: 37604268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
    Said A; Akhter A
    Ann Hepatol; 2017; 16(4):538-547. PubMed ID: 28611274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials.
    Pai RK; Kleiner DE; Hart J; Adeyi OA; Clouston AD; Behling CA; Jain D; Kakar S; Brahmania M; Burgart L; Batts KP; Valasek MA; Torbenson MS; Guindi M; Wang HL; Ajmera V; Adams LA; Parker CE; Feagan BG; Loomba R; Jairath V
    Aliment Pharmacol Ther; 2019 Nov; 50(10):1100-1111. PubMed ID: 31583739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The HAALT Non-invasive Scoring System for NAFLD in Obesity.
    Sheth H; Bagasrawala S; Shah M; Ansari R; Olithselvan A; Lakdawala M
    Obes Surg; 2019 Aug; 29(8):2562-2570. PubMed ID: 31016455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease progression of nonalcoholic steatohepatitis in Taiwanese patients: a longitudinal study of paired liver biopsies.
    Lin TY; Yeh ML; Huang CF; Huang CI; Dai CY; Hsieh MH; Chen SC; Huang JF; Yu ML; Chuang WL
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):224-229. PubMed ID: 30308578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide.
    Kamm DR; Pyles KD; Sharpe MC; Healy LN; Colca JR; McCommis KS
    J Biol Chem; 2021; 296():100807. PubMed ID: 34022222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
    Bril F; McPhaul MJ; Caulfield MP; Clark VC; Soldevilla-Pico C; Firpi-Morell RJ; Lai J; Shiffman D; Rowland CM; Cusi K
    Diabetes Care; 2020 Feb; 43(2):290-297. PubMed ID: 31604692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.
    Poynard T; Paradis V; Mullaert J; Deckmyn O; Gault N; Marcault E; Manchon P; Si Mohammed N; Parfait B; Ibberson M; Gautier JF; Boitard C; Czernichow S; Larger E; Drane F; Castille JM; Peta V; Brzustowski A; Terris B; Vallet-Pichard A; Roulot D; Laouénan C; Bedossa P; Castera L; Pol S; Valla D;
    Aliment Pharmacol Ther; 2021 Oct; 54(7):952-966. PubMed ID: 34398492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acidophil bodies in nonalcoholic steatohepatitis.
    Yeh MM; Belt P; Brunt EM; Kowdley KV; Wilson LA; Ferrell L;
    Hum Pathol; 2016 Jun; 52():28-37. PubMed ID: 26980020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
    Ratziu V; Sanyal AJ; Loomba R; Rinella M; Harrison S; Anstee QM; Goodman Z; Bedossa P; MacConell L; Shringarpure R; Shah A; Younossi Z
    Contemp Clin Trials; 2019 Sep; 84():105803. PubMed ID: 31260793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the histological variability of core and wedge biopsies in nonalcoholic fatty liver disease in bariatric surgical patients.
    Ooi GJ; Clouston A; Johari Y; Kemp WW; Roberts SK; Brown WA; Burton PR
    Surg Endosc; 2021 Mar; 35(3):1210-1218. PubMed ID: 32170564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deep learning-based quantification of NAFLD/NASH progression in human liver biopsies.
    Heinemann F; Gross P; Zeveleva S; Qian HS; Hill J; Höfer A; Jonigk D; Diehl AM; Abdelmalek M; Lenter MC; Pullen SS; Guarnieri P; Stierstorfer B
    Sci Rep; 2022 Nov; 12(1):19236. PubMed ID: 36357500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation.
    Sourianarayanane A; Arikapudi S; McCullough AJ; Humar A
    Eur J Gastroenterol Hepatol; 2017 Apr; 29(4):481-487. PubMed ID: 28253211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
    Ampuero J; Aller R; Gallego-Durán R; Crespo J; Abad J; González-Rodríguez Á; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Martín-Mateos R; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Hernández-Guerra M; Augustín S; Pareja-Megia MJ; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero-Gómez M;
    Liver Int; 2021 Sep; 41(9):2076-2086. PubMed ID: 33896100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems.
    Schmitz SM; Kroh A; Ulmer TF; Andruszkow J; Luedde T; Brozat JF; Neumann UP; Alizai PH
    BMC Gastroenterol; 2020 Aug; 20(1):254. PubMed ID: 32758151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study.
    Sanyal AJ; Loomba R; Anstee QM; Ratziu V; Kowdley KV; Rinella ME; Harrison SA; Resnick MB; Capozza T; Sawhney S; Shelat N; Younossi ZM
    Hepatol Commun; 2024 Jan; 8(1):. PubMed ID: 38126958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and Shadows.
    Rowe IA
    Semin Liver Dis; 2020 Nov; 40(4):339-345. PubMed ID: 32906165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis.
    Lassailly G; Caiazzo R; Ntandja-Wandji LC; Gnemmi V; Baud G; Verkindt H; Ningarhari M; Louvet A; Leteurtre E; Raverdy V; Dharancy S; Pattou F; Mathurin P
    Gastroenterology; 2020 Oct; 159(4):1290-1301.e5. PubMed ID: 32553765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM; Sanyal AJ
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The therapeutic landscape of non-alcoholic steatohepatitis.
    Perazzo H; Dufour JF
    Liver Int; 2017 May; 37(5):634-647. PubMed ID: 27727520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.